Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 11/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507576 | 0.88 | AURKA (0.62) | AURKAKDRAURKBCHEK1AKR1B10 | |
| SCHEMBL6507426 | 0.82 | CHEK1 (0.71) | AURKAKDRAURKBCHEK1AKR1B10 | |
| SCHEMBL6507581 | 0.81 | CHEK1 (0.72) | AURKAKDRAURKBCHEK1LMNA | |
| SCHEMBL6523086 | 0.80 | AURKA (0.57) | AURKAKDRAURKBCHEK1AKR1B10 | |
| SCHEMBL6506848 | 0.79 | AURKA (0.59) | AURKAKDRAURKBCHEK1AKR1B10 | |
| SCHEMBL6510076 | 0.78 | AURKA (0.57) | AURKAKDRAURKBCHEK1AKR1B10 | |
| SCHEMBL6508848 | 0.77 | AURKA (0.54) | AURKAKDRAURKBCHEK1AKR1B10 | |
| SCHEMBL6517711 | 0.77 | CHEK1 (0.55) | AURKAKDRAURKBCHEK1KCNH2 | |
| SCHEMBL6522349 | 0.76 | AURKA (0.62) | AURKAKDRAURKBCHEK1LMNA | |
| SCHEMBL6508702 | 0.75 | CHEK1 (0.56) | AURKAKDRAURKBCHEK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | AURKA 78/4885KDR 1094/4885AURKB 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.